Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug

Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.